Atara Biotherapeutics (ATRA) Stock Price Up 6.9%

Atara Biotherapeutics Inc (NASDAQ:ATRA)’s share price rose 6.9% on Tuesday . The stock traded as high as $43.80 and last traded at $43.50. Approximately 1,130,800 shares were traded during trading, an increase of 56% from the average daily volume of 726,445 shares. The stock had previously closed at $40.70.

ATRA has been the subject of several recent research reports. Zacks Investment Research lowered shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 3rd. Citigroup cut their target price on shares of Atara Biotherapeutics from $25.00 to $23.00 and set a “sell” rating for the company in a report on Monday, June 11th. Jefferies Financial Group reaffirmed a “buy” rating and set a $45.00 target price on shares of Atara Biotherapeutics in a report on Friday, August 3rd. Finally, BidaskClub lowered shares of Atara Biotherapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, June 27th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $43.17.

The firm has a market cap of $1.81 billion, a price-to-earnings ratio of -10.88 and a beta of 2.54.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Wednesday, August 1st. The biotechnology company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.17). equities analysts predict that Atara Biotherapeutics Inc will post -4.58 EPS for the current fiscal year.

In related news, EVP Christopher Haqq sold 775 shares of the business’s stock in a transaction on Wednesday, August 15th. The shares were sold at an average price of $37.54, for a total value of $29,093.50. Following the completion of the sale, the executive vice president now owns 331,355 shares of the company’s stock, valued at approximately $12,439,066.70. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Joe Newell sold 10,000 shares of the business’s stock in a transaction on Monday, July 30th. The stock was sold at an average price of $35.78, for a total transaction of $357,800.00. Following the completion of the sale, the insider now directly owns 41,858 shares of the company’s stock, valued at approximately $1,497,679.24. The disclosure for this sale can be found here. In the last three months, insiders sold 142,675 shares of company stock valued at $5,593,522. 10.60% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Northern Trust Corp increased its holdings in Atara Biotherapeutics by 27.1% in the 2nd quarter. Northern Trust Corp now owns 497,371 shares of the biotechnology company’s stock worth $18,278,000 after acquiring an additional 105,935 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Atara Biotherapeutics by 3.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 178,642 shares of the biotechnology company’s stock worth $6,565,000 after acquiring an additional 6,459 shares in the last quarter. MetLife Investment Advisors LLC increased its holdings in Atara Biotherapeutics by 25.1% in the 2nd quarter. MetLife Investment Advisors LLC now owns 18,837 shares of the biotechnology company’s stock worth $692,000 after acquiring an additional 3,781 shares in the last quarter. Metropolitan Life Insurance Co. NY increased its holdings in Atara Biotherapeutics by 25.6% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 13,303 shares of the biotechnology company’s stock worth $489,000 after acquiring an additional 2,715 shares in the last quarter. Finally, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp increased its holdings in Atara Biotherapeutics by 40.6% in the 2nd quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 45,030 shares of the biotechnology company’s stock worth $1,655,000 after acquiring an additional 13,000 shares in the last quarter.

Atara Biotherapeutics Company Profile (NASDAQ:ATRA)

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Further Reading: Asset Allocation Models, Which is Right For You?

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply